Sarcoma, Ewing clinical trials

The registry lists 250 studies for Sarcoma, Ewing across more than 10 countries. 69 are recruiting or about to start. 130 of them are mainly about Sarcoma, Ewing (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Sarcoma, Ewing studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 105
Recruiting: 58
Active, not recruiting: 28
Terminated: 23
Status unknown: 13
Not yet recruiting: 10

Phase

Phase 2: 114
Phase 1: 107
Phase 3: 10
Early Phase 1: 2
Phase 4: 1

Where

United States: 167
Italy: 29
France: 25
China: 22
Spain: 18
Canada: 18

Who runs them

National Cancer Institute (NCI) (31) · St. Jude Children's Research Hospital (12) · Peking University People's Hospital (11) · Istituto Ortopedico Rizzoli (9) · Children's Oncology Group (7) · Dana-Farber Cancer Institute (6) · Memorial Sloan Kettering Cancer Center (5) · Emory University (5)

What is being tested here

Drugs under test in Sarcoma, Ewing studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Irinotecan	4	2	13
Cabozantinib	4	0	7
Temozolomide	3	1	13
Cyclophosphamide	3	0	11
Doxorubicin	2	1	9
Liposomal doxorubicin	2	0	4
Zoledronic Acid	2	1	3
PM 01183	2	0	3
Irinotecan sucrosofate	2	0	2
Vincristine	1	0	6

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 7 open · Alkylating agents 5 open · PARP inhibitors 2 open · Antimitotic agents 1 open · Antimetabolites 1 open

Coming up

2phase 3 studies under way

29studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Dec 2026Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors · Bambino Gesù Hospital and Research Institute
Dec 2026Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors · Valent Technologies, LLC
Dec 2026Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors · University of Wisconsin, Madison
Dec 2026Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors · South Plains Oncology Consortium
Dec 2026Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas · Institut Bergonié
Dec 2026Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma · St. Jude Children's Research Hospital
Dec 2026Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies · New York Medical College
Dec 2026Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery · Istituto Ortopedico Rizzoli
Jan 2027Reduced Intensity Haploidentical BMT for High Risk Solid Tumors · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 2027Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD · Dana-Farber Cancer Institute

Who these studies take

Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger. 49 (84%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 2 (3%) take healthy volunteers.

Recruiting studies that take each age, of 58
Age	Women	Men
10	37 (64%)	37 (64%)
18	57 (98%)	56 (97%)
30	46 (79%)	45 (78%)
40	37 (64%)	36 (62%)
50	28 (48%)	28 (48%)
65	25 (43%)	25 (43%)
75	25 (43%)	25 (43%)
85	22 (38%)	22 (38%)

Across all 250 studies, recruiting or not: 64% stop at 75 or younger and 60% at 65; 92% take children; 1% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sarcoma, Ewing studies take

Of 41 phase 1 interventional studies under Sarcoma, Ewing, half reached primary completion within 89 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	89 mo65–134 · 41 studies	—	—
Phase 1/2	51 mo40–84 · 27 studies	—	—
Phase 2	55 mo41–92 · 39 studies	—	56 mo49–92 · 34 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 250. Browse all 250 → or search them.